163 related articles for article (PubMed ID: 19164359)
1. Rate of progression of lung function impairment in alpha1-antitrypsin deficiency.
Dawkins PA; Dawkins CL; Wood AM; Nightingale PG; Stockley JA; Stockley RA
Eur Respir J; 2009 Jun; 33(6):1338-44. PubMed ID: 19164359
[TBL] [Abstract][Full Text] [Related]
2. Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV
Fähndrich S; Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R
Respir Med; 2017 Aug; 129():8-15. PubMed ID: 28732839
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal changes in physiological, radiological, and health status measurements in alpha(1)-antitrypsin deficiency and factors associated with decline.
Dowson LJ; Guest PJ; Stockley RA
Am J Respir Crit Care Med; 2001 Nov; 164(10 Pt 1):1805-9. PubMed ID: 11734427
[TBL] [Abstract][Full Text] [Related]
4. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease.
Nishimura M; Makita H; Nagai K; Konno S; Nasuhara Y; Hasegawa M; Shimizu K; Betsuyaku T; Ito YM; Fuke S; Igarashi T; Akiyama Y; Ogura S;
Am J Respir Crit Care Med; 2012 Jan; 185(1):44-52. PubMed ID: 22016444
[TBL] [Abstract][Full Text] [Related]
5. Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?
Stockley RA; Edgar RG; Pillai A; Turner AM
Int J Chron Obstruct Pulmon Dis; 2016; 11():1745-56. PubMed ID: 27536086
[TBL] [Abstract][Full Text] [Related]
6. Decline in FEV
Hiller AM; Piitulainen E; Jehpsson L; Tanash H
Int J Chron Obstruct Pulmon Dis; 2019; 14():1075-1083. PubMed ID: 31213789
[No Abstract] [Full Text] [Related]
7. Relationship between frequency, length, and treatment outcome of exacerbations to baseline lung function and lung density in alpha-1 antitrypsin-deficient COPD.
Vijayasaratha K; Stockley RA
Int J Chron Obstruct Pulmon Dis; 2012; 7():789-96. PubMed ID: 23226015
[TBL] [Abstract][Full Text] [Related]
8. Correlation between annual change in health status and computer tomography derived lung density in subjects with alpha1-antitrypsin deficiency.
Stolk J; Ng WH; Bakker ME; Reiber JH; Rabe KF; Putter H; Stoel BC
Thorax; 2003 Dec; 58(12):1027-30. PubMed ID: 14645966
[TBL] [Abstract][Full Text] [Related]
9. The rapid FEV(1) decline in chronic obstructive pulmonary disease is associated with predominant emphysema: a longitudinal study.
Cerveri I; Corsico AG; Grosso A; Albicini F; Ronzoni V; Tripon B; Imberti F; Galasso T; Klersy C; Luisetti M; Pistolesi M
COPD; 2013 Feb; 10(1):55-61. PubMed ID: 23272662
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor.
Wencker M; Fuhrmann B; Banik N; Konietzko N;
Chest; 2001 Mar; 119(3):737-44. PubMed ID: 11243951
[TBL] [Abstract][Full Text] [Related]
11. Radiologic and clinical features of COPD patients with discordant pulmonary physiology: lessons from alpha1-antitrypsin deficiency.
Holme J; Stockley RA
Chest; 2007 Sep; 132(3):909-15. PubMed ID: 17573491
[TBL] [Abstract][Full Text] [Related]
12. Predictors of mortality in alpha1-antitrypsin deficiency.
Dawkins PA; Dowson LJ; Guest PJ; Stockley RA
Thorax; 2003 Dec; 58(12):1020-6. PubMed ID: 14645964
[TBL] [Abstract][Full Text] [Related]
13. α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained.
Sclar DA; Evans MA; Robison LM; Skaer TL
Clin Drug Investig; 2012 May; 32(5):353-60. PubMed ID: 22480280
[TBL] [Abstract][Full Text] [Related]
14. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.
Decramer M; Celli B; Kesten S; Lystig T; Mehra S; Tashkin DP;
Lancet; 2009 Oct; 374(9696):1171-8. PubMed ID: 19716598
[TBL] [Abstract][Full Text] [Related]
15. Emphysematous phenotype is an independent predictor for frequent exacerbation of COPD.
Oh YM; Sheen SS; Park JH; Jin UR; Yoo JW; Seo JB; Yoo KH; Lee JH; Kim TH; Lim SY; Yoon HI; Lee JS; Lee SD
Int J Tuberc Lung Dis; 2014 Dec; 18(12):1407-14. PubMed ID: 25517804
[TBL] [Abstract][Full Text] [Related]
16. Quantitative airway assessment on computed tomography in patients with alpha1-antitrypsin deficiency.
Yamashiro T; Matsuoka S; Estépar RS; Diaz A; Newell JD; Sandhaus RA; Mergo PJ; Brantly ML; Murayama S; Reilly JJ; Hatabu H; Silverman EK; Washko GR
COPD; 2009 Dec; 6(6):468-77. PubMed ID: 19938971
[TBL] [Abstract][Full Text] [Related]
17. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy.
Dirksen A; Dijkman JH; Madsen F; Stoel B; Hutchison DC; Ulrik CS; Skovgaard LT; Kok-Jensen A; Rudolphus A; Seersholm N; Vrooman HA; Reiber JH; Hansen NC; Heckscher T; Viskum K; Stolk J
Am J Respir Crit Care Med; 1999 Nov; 160(5 Pt 1):1468-72. PubMed ID: 10556107
[TBL] [Abstract][Full Text] [Related]
18. Maximal mid-expiratory flow detects early lung disease in α
Stockley JA; Ismail AM; Hughes SM; Edgar R; Stockley RA; Sapey E
Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28356373
[TBL] [Abstract][Full Text] [Related]
19. Association of the transfer coefficient of the lung for carbon monoxide with emphysema progression in male smokers.
Mohamed Hoesein FA; Zanen P; van Ginneken B; van Klaveren RJ; Lammers JW
Eur Respir J; 2011 Nov; 38(5):1012-8. PubMed ID: 21565924
[TBL] [Abstract][Full Text] [Related]
20. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group.
Seersholm N; Wencker M; Banik N; Viskum K; Dirksen A; Kok-Jensen A; Konietzko N
Eur Respir J; 1997 Oct; 10(10):2260-3. PubMed ID: 9387950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
